Better EFS Outcomes with Perioperative Durvalumab Plus FLOT Than with Placebo Plus FLOT for Resectable Gastric or GEJ Adenocarcinoma By Ogkologos - June 10, 2025 505 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Generic Nilotinib August 16, 2024 Resource Round-Up: Let’s Win Pancreatic Cancer May 23, 2023 Cómo comenzar a hacer ejercicio en el hogar durante el tratamiento... January 18, 2023 FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Carcinoma April 5, 2022 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib PSMA PET-CT Accurately Detects Prostate Cancer Spread, Trial Shows Why people and culture matter in research Virchow: The Largest Foundation Model for Computational Pathology To Date
